

Neurology

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF NEUROLOGY

OCTOBER 1996

VOLUME 47

NUMBER 4

SUPPLEMENT 2
TO NEUROLOGY
VOLUME 47

ADVANCES IN AMYOTROPHIC LATERAL SCLEROSIS

Ludwig Gutmann, MD
Hiroshi Mitsumoto, MD
Supplement Editors



Little, Brown and Company



Little, Brown and Company

Nancy Megley *Associate Publisher*
Sarah Merrigan *Managing Editor*
Maureen A. Hurley *Assistant Managing Editor*
Janet E. Timmerman *Assistant Managing Editor*
Marlena Faxon *Production Assistant*
Anne Orens *Manager, Sales, Marketing and Circulation*

Publishing Offices: 34 Beacon St., Boston, MA 02108. Telephone:
(617) 859-5637; Fax: (617) 267-3507.

This supplement to *Neurology* was produced by Little, Brown and Company, Boston, Massachusetts. Its publication was supported by an educational grant from Rhône-Poulenc Rorer, Collegetown, Pennsylvania. The supplement was prepared for publication by CoMed Communications, Inc., Philadelphia, Pennsylvania from the colloquium on *Advances in Amyotrophic Lateral Sclerosis*, on January 12–13, 1996, held in Orlando, Florida. The views and opinions expressed in this supplement are those of the participants and authors and do not necessarily reflect the views of the American Academy of Neurology; Little, Brown and Company; Rhône-Poulenc Rorer; or CoMed Communications, Inc.

The Editor-in-Chief, with advice from members of the Editorial Board, reviews requests for publication of symposia on topics of interest to readers of *Neurology*. The decision to publish a symposium as a supplement to *Neurology* is based on the topic, the supplement editors, and the contributors. Once a decision is made to publish a symposium as a supplement, it is not peer reviewed by the Editorial Board of *Neurology*. The individual authors are responsible for their own contributions, and the supplement editors are responsible for the overall quality of the supplement.

Supplement to NEUROLOGY (ISSN 0028-3878). Published monthly by Little, Brown and Company, 34 Beacon Street, Boston, MA 02108-1493. Academy members should send address changes and subsequent inquiries to the American Academy of Neurology, 2221 University Ave. S.E., Suite 335, Minneapolis, MN 55414 (or call 612-623-8115). Non-Academy members should send address changes and subscription inquiries to Little, Brown and Company, Medical Journal Subscription Department, 34 Beacon St, Boston, MA 02108-1493 (or call 1-800-628-4221, fax 617-267-3507).

Subscription rates (sold on volume year or calendar year basis only): Personal subscription, U.S. and possessions, \$180.00; Canada, \$210.00; rest of world (includes Mexico, excludes Japan), \$285.00; Institutional, U.S., \$235.00; Canada, \$265.00; rest of world, \$348.00. Special rates for students, interns, and residents per year: U.S., \$119.00; Canada, \$139.00; rest of world, \$206.00. (PLEASE ADD 7% CANADIAN GST FOR ALL CANADIAN SUBSCRIP-

TIONS. GST NUMBER: R128537917). Single copies \$20.00 prepaid. Overseas subscription rates include expedited delivery charge. In Japan please contact our exclusive agent for prices and subscription information: Igaku-Shoin Ltd., Foreign Publications Dept., Tokyo International, P.O. Box 5063, 1-28-36 Hongo, Bunkyo-Ku, Tokyo 113, Japan.

Neurology is indexed in Index Medicus, Excerpta Medica, Biological Abstracts, Psychological Abstracts, and Current Contents (Life Sciences and Clinical Medicine).

All rights reserved. Copyright © 1996 by the American Academy of Neurology. Except as authorized in the accompanying statement, no part of *Neurology* may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without the publisher's written permission. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the American Academy of Neurology for libraries and other users registered with the Copyright Clearance Center Transactional Reporting Service, provided that the per-copy fee of \$3.00 is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. Call (508) 750-8400 or fax (508) 750-4744 for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This authorization does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Neurology

Official Journal of the American Academy of Neurology

October 1996 Volume 47 Suppl 2

Introduction

- S17 Advances in ALS
L. Gutmann and H. Mitsumoto

Pathogenesis

- S19 Excitotoxicity hypothesis
J.D. Rothstein
- S27 Molecular genetic basis of familial ALS
T. Siddique, D. Nijhawan, and A. Hentati
- S36 Cell death mechanisms in ALS
D.E. Bredesen, M. Wiedau-Pazos, J.J. Goto, S. Rabizadeh, J.A. Roe, E.B. Gralla, L.M. Ellerby, and J.S. Valentine
- S40 Autoimmunity and ALS
R.G. Smith, L. Siklos, M.E. Alexianu, J.I. Engelhardt, D.R. Mosier, L. Colom, A. Habib Mohamed, and S.H. Appel
- S47 Motor neuron growth factors
J.L. Elliott and W.D. Snider
- S54 Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease
D.W. Cleveland, L.I. Bruijn, P.C. Wong, J.R. Marszalek, J.D. Vechio, M.K. Lee, X.-S. Xu, D.R. Borchelt, S.S. Sisodia, and D.L. Price
- S63 Neuropathology of ALS: An overview
A. Hirano

Clinical trials and future research

- S67 Diagnostic criteria in clinical trials
M.H. Brooke
- S71 Natural history of ALS: Symptoms, strength, pulmonary function, and disability
B.R. Brooks
- S83 Development of measurement techniques
T.L. Munsat
- S86 Clinical trials of riluzole in patients with ALS
R.G. Miller, J.P. Bouchard, P. Duquette, A. Eisen, D. Gelinas, Y. Harati, T.L. Munsat, L. Powe, J. Rothstein, P. Salzman, R.L. Sufit, and the ALS/Riluzole Study Group-II

- S93 Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study
D.J. Lange, K.J. Felice, B.W. Festoff, M.J. Gawel, D.F. Gelinas, R. Kratz, E.C. Lai, M.F. Murphy, H.M. Natter, F.H. Norris, S. Rudnicki, and the North American ALS/IGF-I Study Group
- S96 Issues in clinical trial design I: Use of natural history controls. A protagonist view
T.L. Munsat
- S98 Issues in clinical trial design I: Use of natural history controls. An antagonist view
R.L. Sufit
- S100 Issues in clinical trial design II: Selection of end point measures
M.B. Bromberg and B.R. Brooks
- S103 Drug combination treatment in patients with ALS: Current status and future directions
H. Mitsumoto and R.K. Olney
- S108 Advances in ALS Workshop Summary: Research and future goals
M.H. Brooke and M.J. Strong

ALS patient care issues

- S113 ALS CARE: A resource for measuring and improving ALS outcomes
F.A. Anderson, Jr., R.G. Miller, and members of the ALS CARE Advisory Board
- S117 The impact of the approval of riluzole
R. Sufit and D. Newman
- S118 Management of ALS: Nutritional care
E.J. Kasarskis and H.E. Neville
- S121 Improving education for physicians and for patients
D.A. Chad and R.G. Miller
- S123 Management of ALS: Respiratory care
L.C. Hopkins, G.T. Tatarian, and T.F. Pianta
- S126 The economic impact of ALS
L.M. Klein and D.A. Forshew

Panel Discussion

- S130 Communications and ALS trial: Information sharing

Advances in Amyotrophic Lateral Sclerosis

This supplement to *Neurology* is based on a colloquium that was held in Orlando, Florida, on January 11 and 13, 1996. The following participated:

Co-Chairs

Ludwig Gutmann
West Virginia University
Health Sciences Center
Morgantown, West Virginia

Hiroshi Mitsumoto
Cleveland Clinic Foundation
Cleveland, Ohio

Advisory Board Members

Michael H. Brooke
Walter C. McKenzie Center
University of Alberta
Edmonton, Alberta
Canada

Yadollah Harati
Baylor College of Medicine
Houston, Texas

Robert G. Miller
California Pacific Medical Center
San Francisco, California

Theodore L. Munsat
New England Medical Center
Boston, Massachusetts

Steven P. Ringel
University of Colorado
Denver, Colorado

Jeffrey D. Rothstein
Department of Neurology
Johns Hopkins University
Baltimore, Maryland

Robert L. Sufit
Northwestern University
Chicago, Illinois

Contributors

Frederick A. Anderson
University of Massachusetts Medical Center
Worcester, Massachusetts

Dale Bredesen
La Jolla Cancer Research Foundation
La Jolla, California

Mark B. Bromberg
University of Utah
Salt Lake City, Utah

Michael H. Brooke
Walter C. McKenzie Center
University of Alberta
Edmonton, Alberta
Canada

Benjamin Rix Brooks
University of Wisconsin
Madison, Wisconsin

Neil Cashman
Montreal Neurological Institute
Montreal, PQ
Canada

David A. Chad
University of Massachusetts Medical Center
Worcester, Massachusetts

Don Cleveland
University of California at San Diego
Ludwig Institute
San Diego, California

Jeffrey L. Elliott
Washington University School of Medicine
St. Louis, Missouri

Dallas A. Forshaw
University of Utah
Salt Lake City, Utah

Deborah F. Gelinas
Forbes Norris MDA/ALS Center
San Francisco, California

Asao Hirano

Albert Einstein Medical Center
Montefiore Medical Center
Bronx, New York

Linton C. Hopkins

The Emory Clinic
Atlanta, Georgia

Edward J. Kasarskis

University of Kentucky
Lexington, Kentucky

Lynn Klein

National Organization of Rare Diseases
New Fairfield, Connecticut

Dale J. Lange

Neurology Institute
New York, New York

Robert G. Miller

California Pacific Medical Center
San Francisco, California

Hiroshi Mitsumoto

ALS Center
Cleveland Clinic
Cleveland, Ohio

Theodore L. Munsat

New England Medical Center
Boston, Massachusetts

Hans E. Neville

University of Colorado and
Veterans Affairs Medical Centers
Denver, Colorado

Daniel S. Newman

Henry Ford Hospital
Detroit, Michigan

Richard K. Olney

University of California
San Francisco, California

Jeffrey D. Rothstein

Johns Hopkins School of Medicine
Baltimore, Maryland

Teepu Siddique

Department of Neurology
Northwestern University Medical School
Chicago, Illinois

Robert Glenn Smith

Baylor College of Medicine
Houston, Texas

William D. Snider

Washington University Medical School
St. Louis, Missouri

Michael J. Strong

University of Western Ontario
London, Ontario
Canada

Robert Sufit

Northwestern University
Chicago, Illinois

Gabriel T. Tatarian

The ALS Clinical Services Center
Philadelphia, Pennsylvania

Charles A. Thornton

University of Rochester
Rochester, New York

Panel Discussion

Michael H. Brooke

University of Alberta
Edmonton, Alberta
Canada

Benjamin Rix Brooks

University of Wisconsin
Madison, Wisconsin

Daniel Drachman

Johns Hopkins Hospital
Baltimore, Maryland

Ludwig Gutmann, Moderator

Eugene C. Lai

Baylor College of Medicine
Houston, Texas

Robert G. Miller

California Pacific Medical Center
San Francisco, California

Theodore L. Munsat

New England Medical Center
Boston, Massachusetts

Neurology[®]

47 (4 Suppl 2)

Neurology 1996;47;108S-92S

This information is current as of October 1, 1996

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/47/4_Suppl_2.citation.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

